Bioengineering lab joins EU consortium on virtual human twins

© 2024 EPFL

© 2024 EPFL

The Laboratory of Hemodynamics and Cardiovascular Technology in the School of Engineering will contribute to a new European research consortium aimed at developing virtual twins for personalized treatment of cardiovascular diseases.

The launch of the EU-funded Horizon Europe VITAL project, which will run from 2024 to 2029, was announced in a July press release. The project aims to develop a framework for digital models that act as dynamic, data-driven digital replicas of individuals, and are continuously updated with real-time health information from clinical exams and wearable sensors. Such models can help healthcare providers tailor therapeutic strategies to each patient, thereby improving treatment outcomes and reducing healthcare costs.

The LHTC in EPFL’s Institute of Bioengineering is led by Nikolaos Stergiopulos. Research focuses on the study of blood flow in relation to cardiovascular disease, and the advancement of cardiovascular technology via knowledge transfer to the clinical and medical technology sectors. The group will contribute to the VITAL project’s endeavor of building a multi-organ computational model of human physiology with their expertise in modelling of arterial hemodynamics and artificial intelligence. The goal is to demonstrate clinically useful applications of personalized multiscale mechanistic models, notably in the diagnosis and treatment of heart failure and hypertension. The lab has joined VITAL thanks to funding from the Swiss State Secretariat for Education, Research and lnnovation (SERI).

The VITAL research consortium brings together other leading universities across Europe (TU Delft, Maastricht University, University of Pisa, Jagiellonian University, Ghent University); the UK (King’s College London and University College London); and New Zealand (Auckland Bioengineering Institute); as well as two research centers (imec in the Netherlands and the Austrian Institute of Technology); two SMEs (ELEM Biotech in Spain and WCR in the Netherlands); and Assistance Publique Hôpitaux de Paris.


Source: Institute of Bioengineering

This content is distributed under a Creative Commons CC BY-SA 4.0 license. You may freely reproduce the text, videos and images it contains, provided that you indicate the author’s name and place no restrictions on the subsequent use of the content. If you would like to reproduce an illustration that does not contain the CC BY-SA notice, you must obtain approval from the author.